Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12N-005/00
A61K-045/06
C12N-005/077
A61K-035/28
출원번호
US-0138083
(2005-05-25)
등록번호
US-9597395
(2017-03-21)
발명자
/ 주소
Fraser, John K.
Hedrick, Marc H.
Zhu, Min
Strem, Brian M.
Daniels, Eric
Wulur, Isabella
출원인 / 주소
Cytori Therapeutics, Inc.
대리인 / 주소
Knobbe Martens Olson & Bear LLP
인용정보
피인용 횟수 :
1인용 특허 :
109
초록▼
Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g., stem and/or progenitor cells, obtained
Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g., stem and/or progenitor cells, obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, adipose derived regenerative cells are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.
대표청구항▼
1. A method of improving cardiac ejection fraction in a subject, comprising: identifying a subject in need of improved cardiac ejection fraction; andproviding to the subject a composition comprising a concentrated population of adipose-derived regenerative cells sufficient to improve cardiac ejectio
1. A method of improving cardiac ejection fraction in a subject, comprising: identifying a subject in need of improved cardiac ejection fraction; andproviding to the subject a composition comprising a concentrated population of adipose-derived regenerative cells sufficient to improve cardiac ejection fraction in said subject, wherein said concentrated population of adipose-derived regenerative cells comprises adipose-derived stem cells and endothelial progenitor cells, and wherein said concentrated population of adipose-derived regenerative cells is obtained by acquiring an adipose tissue sample, separating away adipocytes and connective tissue, and washing and concentrating said adipose-derived regenerative cells. 2. The method of claim 1, wherein the subject is human. 3. The method of claim 1, wherein said concentrated population of adipose-derived regenerative cells comprises precursor cells. 4. The method of claim 1, wherein said composition is provided to said subject in a bolus. 5. The method of claim 1, wherein said composition is provided to said subject in multiple doses. 6. The method of claim 1, wherein the composition is provided to said subject via at least one of an endomyocardial, epimyocardial, intraventricular, intracoronary, retrograde coronary sinus, intra-arterial, intra-pericardial, or intravenous administration route. 7. A method of improving cardiac perfusion in a subject, comprising: identifying a subject with insufficient cardiac perfusion; andproviding to the subject a composition that comprises an amount of a concentrated population of adipose-derived regenerative cells sufficient to improve cardiac perfusion in said subject, wherein said concentrated population of adipose-derived regenerative cells comprises stem cells and endothelial progenitor cells, and wherein said concentrated population of adipose-derived regenerative cells is obtained by acquiring an adipose tissue sample, separating away adipocytes and connective tissue, and washing and concentrating said adipose-derived regenerative cells. 8. The method of claim 7, wherein the subject is human. 9. The method of claim 7, wherein said concentrated population of adipose-derived regenerative cells comprises precursor cells. 10. The method of claim 7, wherein said composition is provided to said subject in a bolus. 11. The method of claim 7, wherein said composition is provided to said subject in multiple doses. 12. The method of claim 7, wherein the composition is provided to said subject via at least one of an endomyocardial, epimyocardial, intraventricular, intracoronary, retrograde coronary sinus, intra-arterial, intra-pericardial, or intravenous administration route. 13. A method for preventing the progression of cardiac remodeling in a subject, comprising: identifying a subject at risk of cardiac remodeling; andproviding to the subject an amount of a composition comprising a concentrated population of adipose-derived regenerative cells is sufficient to prevent the progression of cardiac remodeling in said subject, wherein said concentrated population of adipose-derived regenerative cells comprises stem cells and endothelial progenitor cells, and wherein said concentrated population of adipose-derived regenerative cells is obtained by acquiring an adipose tissue sample, separating away adipocytes and connective tissue, and washing and concentrating said adipose-derived regenerative cells. 14. The method of claim 13, wherein the subject is human. 15. The method of claim 13, wherein said concentrated population of adipose-derived regenerative cells comprises precursor cells. 16. The method of claim 13, wherein said composition is provided to said subject in a bolus. 17. The method of claim 13, wherein said composition is provided to said subject in multiple doses. 18. The method of claim 13, wherein the composition is provided to said subject via at least one of an endomyocardial, epimyocardial, intraventricular, intracoronary, retrograde coronary sinus, intra-arterial, intra-pericardial, or intravenous administration route. 19. The method of claim 1, wherein said concentrated population of adipose-derived regenerative cells is isolated in a closed system. 20. The method of claim 7, wherein said concentrated population of adipose-derived regenerative cells is isolated in a closed system. 21. The method of claim 13, wherein said concentrated population of adipose-derived regenerative cells is isolated in a closed system. 22. The method of claim 1, wherein said concentrated population of adipose-derived regenerative cells is not cultured. 23. The method of claim 7, wherein said concentrated population of adipose-derived regenerative cells is not cultured. 24. The method of claim 13, wherein said concentrated population of adipose-derived regenerative cells is not cultured. 25. The method of claim 19, wherein said concentrated population of adipose-derived regenerative cells is not cultured. 26. The method of claim 20, wherein said concentrated population of adipose-derived regenerative cells is not cultured. 27. The method of claim 21, wherein said concentrated population of adipose-derived regenerative cells is not cultured. 28. The method of claim 1, wherein said concentrated population of adipose-derived regenerative cells further comprises an additive. 29. The method of claim 28, wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, a growth factor, a tissue or cell re-aggregation inhibitor, and a scaffold, or any combination thereof. 30. The method of claim 7, wherein said concentrated population of adipose-derived regenerative cells further comprises an additive. 31. The method of claim 30, wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, a growth factor, a tissue or cell re-aggregation inhibitor, and a scaffold, or any combination thereof. 32. The method of claim 13, wherein said concentrated population of adipose-derived regenerative cells further comprises an additive. 33. The method of claim 32, wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, a growth factor, a tissue or cell re-aggregation inhibitor, and a scaffold, or any combination thereof. 34. The method of claim 1, wherein said step of providing to the subject a composition comprising a concentrated population of adipose-derived regenerative cells improves exercise tolerance in said subject. 35. The method of claim 34, wherein the subject is human. 36. The method of claim 34, wherein the concentrated population of adipose-derived regenerative cells comprises precursor cells. 37. The method of claim 34, wherein the composition is provided to said subject in a bolus. 38. The method of claim 34, wherein the composition is provided to said subject in multiple doses. 39. The method of claim 34, wherein the composition is provided to said subject via at least one of an endomyocardial, epimyocardial, intraventricular, intracoronary, retrograde coronary sinus, intra-arterial, intra-pericardial, or intravenous administration route. 40. The method of claim 34, wherein said concentrated population of adipose-derived regenerative cells is isolated in a closed system. 41. The method of claim 34, wherein said concentrated population of adipose-derived regenerative cells is not cultured. 42. The method of claim 40, wherein said concentrated population of adipose-derived regenerative cells is not cultured. 43. The method of claim 34, wherein said concentrated population of adipose-derived regenerative cells further comprises an additive. 44. The method of claim 43, wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, a growth factor, a tissue or cell re-aggregation inhibitor, and a scaffold, or any combination thereof. 45. The method of claim 1, wherein said subject has acute myocardial infarction. 46. The method of claim 1, wherein said subject has ischemic heart disease. 47. The method of claim 7, wherein said subject has acute myocardial infarction. 48. The method of claim 7, wherein said subject has ischemic heart disease. 49. The method of claim 13, wherein said subject has acute myocardial infarction. 50. The method of claim 13, wherein said subject has ischemic heart disease. 51. The method of claim 1, wherein the composition provides a minimum concentration of 5.5×104 adipose-derived cells. 52. The method of claim 7, wherein the composition provides a minimum concentration of 5.5×104 adipose-derived cells. 53. The method of claim 13, wherein the composition provides a minimum concentration of 5.5×104 adipose-derived cells. 54. The method of claim 1, wherein the frequency of stem cells in the concentrated population of adipose-derived regenerative cells is at least 0.1%. 55. The method of claim 7, wherein the frequency of stem cells in the concentrated population of adipose-derived regenerative cells is at least 0.1%. 56. The method of claim 13, wherein the frequency of stem cells in the concentrated population of adipose-derived regenerative cells is at least 0.1%. 57. The method of claim 7, wherein said step of providing to the subject a composition comprising a concentrated population of adipose-derived regenerative cells improves exercise tolerance in said subject. 58. The method of claim 13, wherein said step of providing to the subject a concentrated composition comprising a population of adipose-derived regenerative cells improves exercise tolerance in said subject. 59. The method of claim 1, wherein said concentrated population of adipose-derived regenerative cells is cryopreserved. 60. The method of claim 7, wherein said concentrated population of adipose-derived regenerative cells is cryopreserved. 61. The method of claim 13, wherein said concentrated population of adipose-derived regenerative cells is cryopreserved.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (109)
Goldman Stephen A. (Cincinnati OH) Retzsch Herbert L. (Cincinnati OH) Mansfield Todd L. (Cincinnati OH), Absorbent members for body fluids having good wet integrity and relatively high concentrations of hydrogel-forming absor.
Katz, Adam J.; Llull, Ramon; Futrell, William J.; Hedrick, Marc H.; Benhaim, Prosper; Lorenz, Hermann Peter; Zhu, Min, Adipose-derived stem cells and lattices.
Giesler Richard ; Chapman John R. ; Ellis Dale R. ; Bischof Daniel F., Apparatus for separation of biologic components from heterogeneous cell populations.
Hedrick, Marc H.; Fraser, John K.; Schulzki, Michael J.; Byrnes, Bobby; Carlson, Grace; Schreiber, Ronda Elizabeth; Wulur, Isabella, Automated methods for isolating and using clinically safe adipose derived regenerative cells.
Sasayama Norihisa,JPX ; Kikuchi Toshihiro,JPX ; Harada Shinichiro,JPX ; Takagi Nobuo,JPX ; Wakabayashi Takahito,JPX, Blood filter set and a method of recovering blood components using the same.
Wolinsky Harvey (New York NY) King Spencer L. (Atlanta GA) Barbere Michael D. (Dunstable MA), Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen.
Lindall Arnold W. (1150 Nordic Ave. North ; P.O. Box 187 Stillwater MN 55082), Catheter system for controllably releasing a therapeutic agent at a remote tissue site.
Dwulet Francis E. ; Smith Marilyn E., Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease.
Lake William C. (Laguna Niguel CA) Giesler Richard (Deerfield IL) Epps Dennis Van (Cary IL) Chapman John R. (Lake Villa IL) Martinson Jeffrey A. (Mundelein IL) Ellis Dale R. (Wonder Lake IL) Aono Fre, Continuous centrifugation process for the separation of biological components from heterogeneous cell populations.
Lake William C. ; Giesler Richard ; Van Epps Dennis ; Chapman John R. ; Martinson Jeffrey A. ; Ellis Dale R. ; Aono Frederick ; Bischof Daniel F., Continuous process for the separation of biologic components from heterogeneous cell populations.
Alchas Paul G. (29 Ponds Cir. Wayne NJ 07470) Prais Alfred W. (245 Awosting Rd. Hewitt NJ 07421) Jarrell Bruce E. (5700 N. Via Elena Tucson AZ 85718) Williams Stuart K. (5181 N. Circulo Sobrio Tucson, Device and method for collecting and processing fat tissue and procuring microvessel endothelial cells to produce endoth.
Alchas, Paul G.; Augello, Frank A.; Brooks, Christopher J.; Cutshall, Tony A.; DiPisa, Jr., Joseph A.; Williams, Stuart K.; Gabel, Jonathan B.; Mulhauser, Paul J.; Prais, Wes; Jarrell, Bruce E.; Rose, Endothelial cell procurement and deposition kit.
Caplan Arnold I. ; Haynesworth Stephen E. ; Gerson Stanton L. ; Lazarus Hillard M., Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells.
Peterson Dale R. ; Nousek-Goebl Nancy, Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration.
Sheng Ping Zhong ; Arthur R. Madenjian ; Douglas E. Godshall ; John M. Ronan ; Samuel A. Thompson, Medical devices comprising hydrogel polymers having improved mechanical properties.
McNally Robert T. (Marietta GA) McCaa Cameron (Marietta GA) Brockbank Kelvin G. M. (Marietta GA) Heacox Albert E. (Marietta GA) Bank Harvey L. (Charleston SC), Method for cryopreserving blood vessels.
Eppley Barry L. (8360 Lakeshore Cir. Indianapolis IN 46250) Krukowski Marilyn D. (24 Washington Ter. St. Louis MO 63112) Osdoby Philip A. (16206 Berry Hollow Ct. Ballwin MO 63011), Method for promoting soft connective tissue growth and repair in mammals.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for treating connective tissue disorders.
Yannas Ioannis V. (Newton Center MA) Burke John F. (Belmont MA) Orgill Dennis P. (Cambridge MA) Skrabut Eugene M. (Beverly MA), Method of promoting the regeneration of tissue at a wound.
Carabasi R. Anthony (Bryn Mawr PA) Jarrell Bruce E. (Philadelphia PA) Williams Stuart K. (Wilmington DE), Method of reendothelializing vascular linings.
Williams Stuart K. (Wilmington DE) Jarrell Bruce E. (Philadelphia PA), Method of treating a synthetic naturally occurring surface with a collagen laminate to support microvascular endothelial.
Williams Stuart K. (Drexel Hill PA) Jarrell Bruce E. (Philadelphia PA), Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surfa.
Lacy Paul E. (63 Marshall Pl. St. Louis MO 63119) Scharp David W. (1469 Willow Brook Cove St. Louis MO 63146) Ricordi Camillo (Corso Porta Nuova 10 20121 Milano ITX), Method to isolate clusters of cell subtypes from organs.
Hedrick, Marc H.; Fraser, John K.; Riley, Susan Lynn; Schreiber, Ronda Elizabeth, Methods of using regenerative cells in the treatment of musculoskeletal disorders.
Hu Can B. (Irvine CA) Ma Minh T. (Santa Ana CA) Nguyen Than (Huntington Beach CA) Rhee Richard (Diamond Bar CA) Myers Keith (El Toro CA), Microvessel cell isolation apparatus.
Tayot Jean-Louis (La Tour de Salvagny FRX) Tardy Michel (Lyons FRX), New preparation of placenta collagen, their extraction method and their applications.
Helmut Burtscher DE; Dorothee Ambrosius DE; Friederike Hesse DE, Recombinant collagenase type I from clostridium histolyticum and its use for isolating cells and groups of cells.
Haller, Markus; Ferek-Petric, Bozidar; Donders, Adrianus P., System and method of communicating between an implantable medical device and a remote computer system or health care provider.
Hedrick, Marc H.; Fraser, John K.; Schulzki, Michael J.; Byrnes, Bobby; Carlson, Grace; Schreiber, Ronda Elizabeth; Wulur, Isabella, Systems and methods for isolating and using clinically safe adipose derived regenerative cells.
Hedrick, Marc H.; Fraser, John K.; Schulzki, Michael J.; Byrnes, Bobby; Carlson, Grace; Schreiber, Ronda; Wulur, Isabella, Systems and methods for isolating and using clinically safe adipose derived regenerative cells.
Hedrick, Marc H.; Fraser, John K.; Schulzki, Michael J.; Byrnes, Bobby; Carlson, Grace; Shanahan, Robert K., Systems and methods for separating and concentrating adipose derived stem cells from tissue.
Gerson Stanton L. (Pepper Pike OH) Caplan Arnold I. (Cleveland Heights OH) Haynesworth Stephen E. (Cleveland Heights OH), Transduced mesenchymal stem cells.
Yuan-Di C. Halvorsen ; William O. Wilkison ; Jeffrey Martin Gimble, Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair.
Clarke Rolf W. (Balboa Island CA) Balding David P. (Mission Viejo CA) Gordon Lucas S. (Lagune Beach CA), Venous reservoir bag with integral high-efficiency bubble removal system.
Wegener, Christopher J.; Olson, Bret M.; Schlinker, Alaina; Binninger, Steven; Kadakia, Avnie A., System and method for processing, incubating, and/or selecting biological cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.